Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2021

View Archived Issues

Surface Ophthalmics initiates phase II trial of SURF-200 for acute dry eye

In vivo data on IHL-675A supports expansion of indications to include COPD and asthma

Thrombin trivalent inhibitors inspired by native peptidic inhibitors from hematophagous arthropods

CD22 is a potential target for CAR T-cell therapy in LBCL after failure of autologous CAR19 therapy

FDA places clinical hold on phase IIa study of SPR-720

Ono Pharmaceutical divulges KDM5A inhibitors

Kymera Therapeutics patents CRBN inhibitors

Pfizer presents new TLR agonists

Scenic Immunology synthesizes new QC and/or QPCTL inhibitors

Good T Cells patents molecules for treating immune checkpoint inhibitor-resistant cancer

Phase III KESTREL study of Imfinzi in HNSCC does not meet its primary or secondary endpoints

SerpinPC found useful in patients with severe hemophilia

FDA approves phase I/IIa study of HDP-101 in multiple myeloma

Single-cell resolution reveals cell type, targets, for neuroblastoma

Updated patient eligibility and first-in-human data for BAY-2599023

Korean MFDS grants conditional marketing authorization for Regkirona for COVID-19

Bevacizumab shows potential benefit in COVID-19 patients

FDA grants accelerated approvals of Ukoniq for marginal zone lymphoma and follicular lymphoma

Phase I/II results for TAK-754 gene therapy in severe hemophilia A

Alphamab initiates phase I/II study of KN-046 with donafenib in HCC

Safety, immune responses reported for SARS-CoV-2 vaccine BBV-152 in clinical trial

PCOS passed on in the epigenes

Preclinical data presented for GD2-B7H3 CART in metastatic neuroblastoma

FDA approves Breyanzi for relapsed or refractory large B-cell lymphoma

Phase I trial of IDE-397 for solid tumors with MTAP deletion cleared to begin in U.S.

FDA clears IND for phase I/II study of PBKR-03 for Krabbe disease

Sinovac reports phase III data on CoronaVac

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...